比卡鲁胺在跨性别女性青少年中的应用回顾性研究：单中心经验
A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience.
作者信息
Fuqua John S, Shi Eda, Eugster Erica A
机构信息
Division of Endocrinology, Department of Pediatrics, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Pediatrics, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.
出版信息
Int J Transgend Health. 2023 Dec 15;25(3):533-537. doi: 10.1080/26895269.2023.2294321. eCollection 2024.
Androgen blockers are an essential part of gender affirming care in post-pubertal transfeminine patients. Bicalutamide is a highly potent androgen receptor blocker that is used primarily in adults. We aimed to review our experience with the use of bicalutamide in transgender adolescents who were assigned male at birth. A retrospective review of medical records of transfeminine patients treated with bicalutamide during an 8-year period was conducted. Forty patients, aged 15.5 ± 1.55 years were identified, of whom 21 (53%) were started on bicalutamide alone and 19 were started concurrently on estrogen. In patients on bicalutamide alone, 90.4% reported breast development at their first follow up visit, which occurred at a median of 7.1 months. Patients were treated for 29.4 ± 18.2 months. No episodes of liver toxicity related to bicalutamide were seen. Although these results are preliminary, bicalutamide appears to be a safe option for androgen blockade in transgender girls.
雄激素阻断剂是青春期后跨性别女性患者性别肯定治疗的重要组成部分。比卡鲁胺是一种高效的雄激素受体阻断剂，主要用于成年人。我们旨在回顾我们在出生时被指定为男性的跨性别青少年中使用比卡鲁胺的经验。对8年间接受比卡鲁胺治疗的跨性别女性患者的病历进行了回顾性研究。确定了40名年龄为15.5±1.55岁的患者，其中21名（53%）仅开始使用比卡鲁胺，19名同时开始使用雌激素。仅使用比卡鲁胺的患者中，90.4%在首次随访时报告有乳房发育，首次随访的中位时间为7.1个月。患者接受治疗的时间为29.4±18.2个月。未观察到与比卡鲁胺相关的肝毒性事件。尽管这些结果是初步的，但比卡鲁胺似乎是跨性别女孩雄激素阻断的一种安全选择。
Zotero 插件